BMS Welcomes New General Manager for Mexico

Biopharmaceutical company Bristol Myers Squibb (BMS) announced the appointment of Oswaldo Bernal as the new General Manager of its subsidiary in Mexico. His priorities include strengthening and empowering all BMS areas in the country to continue investing in clinical research and medical education while generating strategic partnerships that allow patients to have transformative solutions and improve their health outcomes.

With over 20 years of experience in the industry, Bernal joined BMS two years ago as the leader of the Hematology and Innovative Medicines unit at BMS Mexico. Of Venezuelan origin, he is a pharmacist from the Central University of Venezuela, has an MBA from the Instituto de Estudios Superiores de Administración (IESA) and recently completed the D-1 Senior Management program at the Pan-American Institute of Senior Business Management (IPADE).

In BMS’ official press release, Bernal shared his excitement about taking on this new role. “Today more than ever, I am committed to unlocking the potential of our diverse team of collaborators to drive innovation and bring new treatment options to the people who need them. I am sure that, together with other key players in the health system, we will keep alive our vision of transforming the lives of patients through science,” he said.

BMS is one of the leading R&D pharmaceutical companies in Mexico. It has been in the country for over 75 years and has invested over US$60 million during the past five years in clinical research, which is reflected in the more than 40 clinical trials it has in the country. BMS focuses on oncology, immunology, hematology and multiple sclerosis, among many others. BMS’s subsidiary in Mexico leads the most important project in breast cancer research protocols, according to the company. Of the 10 authors of the protocol, three are Mexican researchers.

Additionally, BMS works closely with the Mexican government, IMSS and some national public health institutes to perform clinical research. The company is focused on launching six innovative treatments by 2024, particularly for hematology and immunology.